Saturday 17 October 2026
Export TLRY’s income statement to Excel — free account
Tilray Brands, Inc.
TLRY Healthcare Drug Manufacturers Specialty & Generic
Tilray Brands, Inc.’s revenue for fiscal 2026 (year ended May 2026) was $915.5 million, up 11.5% from fiscal 2025. In the quarter to August 2026, revenue grew 22.7%, EPS was flat, free cash flow fell 36.6% and total debt rose 43.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.04
0.17
−5.30%
Follow TLRY
| Aug '26 | May '26 | Feb '26 | Nov '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
4 | 3 | 3 | 3 |
+8 more TTM periods Free account |
| (10.50%) | (7.87%) | (63.61%) | (84.30%) | ||
| (7.45%) | (5.52%) | (49.09%) | (67.01%) | ||
ROIC |
(3.21%) | (2.27%) | (59.65%) | (89.19%) | |
Return on Tangible Assets |
(15.75%) | (10.90%) | (133.90%) | (206.60%) | |
Average Days of Receivables |
72.24 | 75.42 | 50.34 | 47.55 | |
Free Cash Flow per Share |
(1.31) | (0.88) | (1.14) | (0.56) | |
Free Cash Flow |
(174.45) | (98.62) | (128.34) | (61.79) | |
Capital Expenditures |
(90.10) | (29.48) | (83.71) | (33.34) | |
| Other line items | |||||
Cash ROIC |
(8.00%) | (4.47%) | (6.14%) | (2.89%) | |
Accounts Receivable Turnover |
6.47 | 5.89 | 7.74 | 7.55 | |
Accounts Payable Turnover |
2.41 | 2.37 | 2.82 | 2.69 | |
Inventory Turnover |
2.23 | 2.29 | 2.23 | 2.19 | |
Average Days of Payables |
179.35 | 177.25 | 131.72 | 137.12 | |
Days of Inventory on Hand |
175.90 | 167.84 | 171.88 | 171.50 | |
Tax Rate |
0.17 | 0.19 | (0.08) | (0.06) | |
Research and Development Expense of Revenue |
0.04% | 0.04% | 0.03% | 0.03% | |
Selling, General and Administrative Expense of Revenue |
33.02% | 32.25% | 31.20% | 30.84% | |
Share Based Compensation of Revenue |
4.93% | 5.02% | 4.33% | 3.28% | |
Interest Coverage |
(3.80) | (2.66) | (70.98) | (91.10) | |
Operating CF/Net income |
0.51 | 0.57 | 0.03 | 0.01 | |
Depreciation/Fixed assets |
0.12 | 0.11 | 0.17 | 0.20 | |
Capex/Depreciation |
(1.15) | (0.39) | (0.90) | (0.31) | |
Revenue per Share |
7.22 | 8.19 | 7.62 | 7.59 | |
Operating CF per Share |
(0.63) | (0.62) | (0.40) | (0.26) | |
Capex per Share |
(0.68) | (0.26) | (0.74) | (0.30) | |
Capex to Sales |
0.09 | 0.03 | 0.10 | 0.04 |
Columns are period end dates · fundamentals updated 13 Oct 2026